SecBot SecBot
PRESS-RELEASE ·Filed Nov 12, 2026

TSHA

Taysha Gene Therapies, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed4d 20h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The key binary catalyst is the 1H 2027 data readout and FDA feedback on the TSHA-102 BLA pathway. Monitor for any safety signals or efficacy trends from the 6-month interim analysis, as well as the outcome of the CMC Type B meeting with FDA in Q4 2026.

DirectionNeutral
Confidencehigh
Horizonmonths

TSHA-102

▲ Bullish Named in this press release
Impact
Phase
Pivotal (registrational)
Time to market
If the 1H 2027 pivotal data and FDA feedback are positive, a BLA submission could follow in 2027-2028, with potential approval in 2028-2029. This timeline depends on the regulatory pathway the FDA outlines.
Next catalyst
None dated

What to watchThe next major binary catalyst is the topline 6-month interim analysis from the REVEAL pivotal trial and FDA feedback on the BLA submission pathway, both expected in the first half of 2027. Positive data and regulatory alignment could open a clear path to approval and drive significant upside; negative data or FDA pushback would be a severe setback for this single-asset company.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$4.21
T+0 close · Nov 12, 2026 · via day close
Latest settled
−2.61%
T+1 · $4.10
Vs SPY
−2.25%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $4.21entry
  2. T+1 · 4d ago −2.61%α −2.25% · $4.10
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Taysha Gene Therapies reported a Q3 2026 net loss of $0.10 per share, narrower than the consensus estimate of a $0.13 loss, with no revenue. The key catalyst is the ongoing TSHA-102 program for Rett syndrome, with topline data from the pivotal trial and FDA feedback on the BLA submission pathway expected in the first half of 2027. The company has $422.8M in cash, sufficient into H2 2028.

Key Financial Metrics

EPS
−$0.10
est −$0.13 · +23.1%
Revenue
$0.00
est $618.0K · -100.0%
Rating
in line

Key Facts

  • Q3 2026 net loss of $39.1M ($0.10 per share) vs consensus $-0.13; no revenue reported.
  • Cash and equivalents of $422.8M as of Sep 30, 2026, expected to fund operations into H2 2028.
  • TSHA-102 (Rett syndrome) pivotal and ASPIRE trials ongoing; all 33 patients cleared acute safety monitoring with no severe SAEs or DLTs.
  • BLA-enabling PPQ manufacturing campaign completed; product met specifications and comparability criteria.
  • Topline data from 6-month interim analysis of REVEAL pivotal trial and FDA feedback on BLA pathway expected in 1H 2027.
  • Company plans to nominate a second CNS gene therapy candidate in 1H 2027.

Financial Impact

Net loss per share of $0.10 beat the consensus estimate of $0.13 by 23.1%. Cash runway extended into H2 2028.

net losscash positionR&D expenses

Risk Factors

  • TSHA-102 clinical trial failure or safety issues could halt the program.
  • FDA may require additional data or studies before accepting a BLA submission.
  • Cash burn rate of ~$40M/quarter; any delays could require additional financing.
  • No approved disease-modifying therapies for Rett syndrome; regulatory path uncertain.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3401459

Track record

14 reports on TSHA

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +20.50% at T+60 after the Jun 25, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $4.06 Now $4.06 −0.00% settles Feb 16
  2. Nov 12, 20264d ago Press Release Neutral 5/10 Viewing Entry $4.21 Now $4.06 −3.56% settles Feb 10
  3. Aug 11, 202613w ago Press Release Neutral 5/10 Entry $6.41 to $4.09 Now $4.06 −36.61% ▼ −36.14% −31.03% vs SPY
  4. Jun 25, 202620w ago 8-K Mixed 5/10 Entry $6.34 to $5.04 Now $4.06 −35.96% ▼ −20.50% −26.61% vs SPY
  5. Jun 25, 202620w ago 424B5 Bearish 6/10 Entry $6.34 to $5.04 Now $4.06 +35.96% ▲ +20.50% +26.61% vs SPY
  6. Jun 24, 202620w ago Press Release Bearish 7/10 Entry $6.21 to $5.02 Now $4.06 +34.62% ▲ +19.16% +22.89% vs SPY
  7. Jun 5, 202623w ago Press Release Neutral 2/10 Entry $5.50 to $5.69 Now $4.06 −26.18% ▲ +3.45% −0.55% vs SPY
  8. May 6, 202627w ago 8-K Neutral 5/10 No price data
  9. May 6, 202627w ago Press Release Mixed 7/10 Entry $6.98 to $5.86 Now $4.06 −41.83% ▼ −16.05% −18.11% vs SPY
  10. Apr 29, 202628w ago Press Release Neutral 1/10 Entry $6.27 to $5.52 Now $4.06 −35.25% ▼ −11.96% −16.07% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 5h 53m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026